BRIEF-Tenaya Therapeutics Doses First Patient In Ridge-1 Phase 1B Clinical Trial Of TN-401

Reuters
25 Nov 2024

Nov 25 (Reuters) - Tenaya Therapeutics Inc :

* TENAYA THERAPEUTICS DOSES FIRST PATIENT IN RIDGE™-1 PHASE 1B CLINICAL TRIAL OF TN-401 FOR THE TREATMENT OF PKP2-ASSOCIATED ARRHYTHMOGENIC RIGHT VENTRICULAR CARDIOMYOPATHY

* TENAYA THERAPEUTICS INC - INITIAL CLINICAL DATA FOR RIDGE-1 EXPECTED IN 2025

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10